Celgene to Acquire Abraxis
In an effort to strengthen its oncology pipeline, Celgene Corporation (Summit, NJ) will acquire California-based Abraxis BioScience Inc. for approximately $2.9 billion in stock and cash. The transaction adds Abraxane, an injectable drug that is approved as a treatment for metastatic breast cancer and is being studied in a number of other solid tumors including lung and pancreatic cancers, to Celgene’s existing portfolio of cancer drugs.
Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58 in cash and 0.2617 shares of Celgene common stock. Each share will also receive one tradeable contingent value right, which entitles its holder to receive payments for future regulatory milestones and commercial royalties. The acquisition of Abraxis is expected to close in the fourth quarter of 2010.
Celgene may explore the application of Abraxane’s “nab” technology to other compounds. Celgene’s two top-selling drugs are Revlimid and Thalomid, which are treatments for multiple myeloma. In January, Celgene acquired Gloucester Pharmaceuticals Inc., gaining the marketed lymphoma drug Istodax.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.